Patients with metastatic colorectal cancer harboring certain BRAF mutations may respond to anti-EGFR

September 12, 2019

Bottom Line: Patients with metastatic colorectal cancer harboring a subset of non-V600 mutations in the BRAF gene, known as class 3 BRAF mutations, were more likely to respond to anti-EGFR treatment.

Journal in Which the Study was Published:Clinical Cancer Research, a journal of the American Association for Cancer Research

Authors: Senior author Hiromichi Ebi, MD, PhD, chief of the Division of Molecular Therapeutics at the Aichi Cancer Center Research Institute in Nagoya, Japan; and first author Rona Yaeger, MD, medical oncologist at Memorial Sloan Kettering Cancer Center

Background: "Cancer genomic profiling is rapidly transforming the clinical management of cancer patients," said Ebi. "Results from our study indicate that metastatic colorectal cancer patients with certain BRAF mutations should be considered for anti-EGFR treatment, a new indication for this population of patients."

Alterations to the RAS signaling pathway, which controls key functions such as cellular proliferation and survival, is a known driver of oncogenesis. Mutations to BRAF, a kinase that interacts with RAS, can result in activation or amplification of the RAS signaling pathway. Roughly 10 percent of metastatic colorectal cancer tumors harbor mutations in the BRAF gene, noted Ebi.

BRAF mutations belong to one of three functional classes. Class 1 comprises BRAF V600 mutations. Non-V600 BRAF mutations are divided into two classes: class 2 mutations are RAS-independent, and class 3 mutations have enhanced binding to RAS and the kinase CRAF, resulting in increased RAS-dependent signaling.

While tumors with V600 BRAF mutations are often susceptible to RAF inhibitors, this therapeutic strategy is not predicted to be successful in tumors with non-V600 BRAF mutations, explained Yaeger. Prior smaller studies have shown that some patients with non-V600 BRAF-mutant colorectal cancer may respond to anti-EGFR treatment, she noted.

How the Study Was Conducted and Results: To determine if different functional classes of non-V600 BRAF mutations affected responses to anti-EGFR therapy, Ebi and colleagues retrospectively analyzed data from 40 patients with metastatic colorectal cancer whose treatment included an anti-EGFR therapy through an international multicenter collaboration. Using biochemical assays, the researchers classified the patients' tumors as having one of the two classes of non-V600 BRAF mutations: 12 patients had class 2 BRAF mutations and 28 patients had class 3 BRAF mutations. Patients from both groups had comparable clinical characteristics.

Eight percent of patients with tumors harboring class 2 BRAF mutations responded to anti-EGFR treatment regimens, compared with 50 percent of those with class 3 BRAF mutations.

The researchers also analyzed responses to anti-EGFR regimens based on treatment line. In the first- or second-line setting, 17 percent of patients with tumors harboring class 2 BRAF mutations responded to treatment, compared with 78 percent of those with class 3 BRAF mutations. In the third-line setting or later, no patients with class 2 BRAF mutations responded to treatment, compared with 37 percent of those with class 3 BRAF mutations.

Author's Comments: "Through the analysis of colorectal cancer tumors with specific BRAF mutations, we identified a potential new indication for anti-EGFR treatment, highlighting the power of precision oncology," noted Ebi.

Study Limitations: Limitations of the study include the small number of patients with metastatic colorectal cancer harboring class 2 or class 3 BRAF mutations. Additionally, because most of the patients analyzed in this study were also treated with chemotherapy, the researchers could not assess the efficacy of anti-EGFR monotherapy based on the functional class of non-V600 BRAF mutations, Ebi noted.
-end-
Funding & Disclosures: This study was supported by a Grant-in-Aid for Scientific Research, Fund for the Promotion of Joint International Research from the Japan Society for the Promotion of Science, the Takeda Science Foundation, a Grant-in-Aid for Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development, a Memorial Sloan Kettering Cancer Center Core grant, and the National Institutes of Health.

Ebi declares no conflict of interest.

American Association for Cancer Research

Related Cancer Patients Articles from Brightsurf:

Higher risk of death in cancer patients with COVID-19 may be due to advanced age and more pre-existing conditions, rather than cancer itself
New research presented at this this week's ESCMID Conference on Coronavirus Diseases (ECCVID, online 23-25 September) suggests that the poor outcomes and higher death rates in cancer patients with COVID-19 could be due to them generally being older and having more underlying conditions, rather than due to the cancer itself.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

The art of cancer caregiving: How art therapies benefits those caring for cancer patients
A recent Drexel University study showed coloring and open-studio art therapy benefits stressed caregivers of cancer patients.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer tissue-freezing approach may help more breast cancer patients in lower income countries
A new reusable device created by the Johns Hopkins University can help women with breast cancer in lower income countries by using carbon dioxide, a widely available and affordable gas, to power a cancer tissue-freezing probe instead of industry-standard argon.

Lots of patients with cancer, cancer survivors use but don't report complementary/alternative medicine therapies
This study used data from a nationwide survey to estimate how many patients with cancer and cancer survivors use complementary and alternative medicines (CAMS) in addition to or instead of conventional therapies, and how many don't disclose that to their physicians.

Colorectal cancer in patients with early onset is distinct from that in older patients
New research indicates that colorectal cancer diagnosed at an early age has clinical and genetic features that are different from those seen in traditional colorectal cancer diagnosed later in life.

Comparable risk of recurrent venous thromboembolism between patients with unprovoked venous thromboembolism and patients with cancer
Patients with venous thromboembolism (VTE) carry a high risk of recurrence.

Personalized cancer vaccine may increase long-term survival in patients with deadly brain cancer
An international Phase III study led by researchers at UCLA has found that a personalized GBM vaccine may increase long-term survival in some patients.

Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.

Read More: Cancer Patients News and Cancer Patients Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.